SCHEMBL24315946

SCHEMBL24315946

CC(C)(C)OC(=O)N1CC(Cc2ccc3c4c(cccc24)NC3=O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
NAMPT P43490 1/20 0.41
BRD4 O60885 3/20 0.41
KDM4E B2RXH2 6/20 0.40
ALDH1A1 P00352 3/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
CREBBP Q92793 1/20 0.39
POLB P06746 2/20 0.38
CRBN Q96SW2 1/20 0.38
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCD Q05655 1/20 0.37
TSHR P16473 1/20 0.37
ALOX5AP P20292 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29610675 1.00 PARP1 (0.41) PARP1NAMPTBRD4KDM4EALDH1A1
SCHEMBL24315948 0.84 KDM4E (0.46) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL29532514 0.84 KDM4E (0.46) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL26621817 0.80 BRD4 (0.38) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL29611226 0.80 BRD4 (0.38) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL24315952 0.80 BRD4 (0.38) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL24315944 0.79 BRD4 (0.38) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL29610452 0.79 BRD4 (0.38) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL29610401 0.79 KDM4E (0.43) PARP1BRD4KDM4EALDH1A1CASP1
SCHEMBL26597817 0.79 KDM4E (0.43) PARP1BRD4KDM4EALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
CN-116783180-A Tricyclic ligands for degradation of IKZF2 or IKZF4 C4医药公司 2023-09-19 CN disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 PARP1 1566/4885NAMPT 3402/4885BRD4 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.